Quick links

Press Releases

Search: From date To date
June 23, 2010 ExAblate® Receives European CE Mark for Treatment of Adenomyosis
April 22, 2010 Innovative technology could transform women’s health across Europe
January 26, 2010 InSightec Announces India Distribution Agreement with Kirloskar
Kirloskar to Distribute ExAblate® 2000 Non-Invasive Magnetic Resonance-guided Focused Ultrasound Systems Throughout the Country
January 13, 2010 First Non-Invasive Technology for Treatment of Uterine Fibroids Awarded MHLW Approval in Japan
November 11, 2009 Non-Invasive Uterine Fibroid Treatment with ExAblate® Shows Significantly Fewer Complications and Faster Recovery than Hysterectomy

Three studies supporting use of ExAblate and Magnetic Resonance-guided Focused Ultrasound (MRgFUS) Published in Ultrasound in Obstetrics and Gynecology

July 14, 2009 A Swiss Team Uses Transcranial MR-Guided Focused Ultrasound to Treat Patients with Functional Brain Disorders
April 7, 2009 FDA APPROVES LABEL CHANGE FOR NON-INVASIVE FIBROID TREATMENT
March 19, 2009 InSightec Ltd. announces $15 Million Investment Round
December 16, 2008 MyCancerPain.org Launched as Resource for Patients with Painful Bone Metastases
December 2, 2008 New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound To Be A Potentially Safe‚ Effective Pain-Relieving Treatment for Bone Metastases
July 21, 2008 First U.S. Patient Undergoes Non-Invasive Magnetic Resonance-Guided Focused Ultrasound Procedure to Relieve Pain from Bone Metastases
May 28, 2008 FDA Clears ExAblate Fertility Enhancement Study in Women with Uterine Fibroids
April 21, 2008 InSightec to Exhibit Non-Invasive Treatment for Uterine Fibroids at 5th Annual World Health Care Congress
December 17, 2007 InSightec Starts Pivotal Study of ExAblate® to Treat Pain Caused by Bone Metastases
December 3, 2007 InSightec Selected as a 2008 World Economic Forum Technology Pioneer
November 29, 2007 InSightec Ltd. announces $30 Million Investment Round
October 16, 2007 InSightec Announces Change to European CE Mark for ExAblate® 2000 in Uterine Fibroids
September 25, 2007 InSightec Resumes Clinical Trials for Non-Invasive Treatment of Brain Tumors
June 6, 2007 InSightec Receives European CE Mark for ExAblate 2000 Treatment of Pain Caused By Bone Metastases
May 14, 2007 InSightec Encourages Uterine Fibroid Sufferers to ask their Doctors about Less Invasive Treatment Options
 
1 2
Next Next